Kei Kishimoto

Kei Kishimoto

Company: Selecta Biosciences

Job title: CSO


Investigating the Potential of Re-Dosing AAV Gene Therapy Vectors for Metabolic Indications 9:00 am

Genetic metabolic disorders often manifest early in childhood with progressive and irreversible sequelae Systemic AAV gene therapy for pediatric patients offers up concerns of durability as liver cells divide, potentially diluting expression Currently re-dosing patients is not possible due to the formation of neutralizing antibodies We are investigating the application of tolerogenic ImmTOR nanoparticles to…Read more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.